Study #2020-0988
Phase Ib/II Study of Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation with Uproleselan Plus Cladribine Plus LDAC in Patients with Treated Secondary AML (TS-AML)
MD Anderson Study Status
Not Accepting
Treatment Agent
Cladribine, Cytarabine, Uproleselan
Description
This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia. Chemotherapy drugs, such as uproleselan, cladribine, and low dose cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Secondary Acute Myeloid Leukemia
Study phase:
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.